AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV

MENU

Search Results for: "Food and Drug Administration"

Health Affairs Press Briefing: The ACA and Vulnerable Americans Living with HIV/AIDS

health affairs cover

On March 11, the health policy journal Health Affairs  hosted a briefing at the National Press Club to highlight its March 2014 edition entitled, “The ACA and Vulnerable Americans: HIV/AIDS; Jails .” The volume features a number of economic and modeling analyses that make a compelling case for the potential impact of the Affordable Care Act (ACA)…

PrEP Topics Examined at CROI 2014

Ronald Valdiserri

Among the many issues being discussed by the scientists, providers, and advocates gathered at the 2014 Conference on Retroviruses and Opportunistic Infections (CROI)  in Boston this week is pre-exposure prophylaxis (PrEP) for HIV. In a number of clinical trials, daily oral PrEP has been proven to be an effective biomedical intervention for reducing the risk…

Online Expert Advice for Clinicians Treating Hepatitis C Now Available

Ronald Valdiserri

Up-to-date guidance for the treatment of hepatitis C virus (HCV) infection is now available for healthcare providers from HCVguidelines.org, a new online resource launched this week by the American Association for the Study of Liver Diseases  (AASLD) and the Infectious Diseases Society of America  (IDSA), in collaboration with the International Antiviral Society-USA   (IAS-USA).  These guidelines are…

FDA approves Sovaldi for chronic hepatitis C

FDA

Drug is third with breakthrough therapy designation to receive FDA approval The U.S. Food and Drug Administration today approved Sovaldi (sofosbuvir) to treat chronic hepatitis C virus (HCV) infection. Sovaldi is the first drug that has demonstrated safety and efficacy to treat certain types of HCV infection without the need for co-administration of interferon. “Today’s…

President Obama Signs Reauthorization of the President’s Emergency Plan for AIDS Relief (PEPFAR)

Dr. Tom Frieden

Ten years ago, HIV/AIDS was devastating the health and wellbeing of millions of individuals in communities across Africa and in other resource-poor countries around the world. Through the President’s Emergency Plan for AIDS Relief (PEPFAR), we have since made extraordinary progress in reducing new HIV infections and providing life-saving care and treatment to those who…

Viral Hepatitis Policy Meets Practice at the Liver Meeting

Photo of author speaking at meeting

Earlier this month, the “Liver Meeting” – the annual meeting of the American Association for the Study of Liver Diseases (AASLD )– took place in Washington, DC. As part of a session re-capping the major viral hepatitis highlights from the conference, I had the pleasure of sharing with several thousand scientists and healthcare professionals from around…

FDA Safety Communication: Reducing the Risk of Hepatitis B Reactivation in Patients Using Two Immune-Suppressing and Anti-Cancer Drugs

FDA

On September 25, 2013, the Food and Drug Administration (FDA) issued a Drug Safety Communication announcing that the FDA has approved changes to the prescribing information of the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab) to add new Boxed Warning information about the risk of reactivation of hepatitis B virus (HBV) infection. The…

FDA approves first rapid diagnostic test to detect both HIV-1 antigen and HIV-1/2 antibodies

FDA

The U.S. Food and Drug Administration today approved the first rapid Human Immunodeficiency Virus (HIV) test for the simultaneous detection of HIV-1 p24 antigen as well as antibodies to both HIV-1 and HIV-2 in human serum, plasma, and venous or fingerstick whole blood specimens. Approved for use as an aid in the diagnosis of HIV-1…

Page 1 of 41234